Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal 
Circle Urges EU to Revise MiCA Stablecoin Rules 
Italgas to Buy 22.5% Stake in Portugal’s Floene for €120 Million 
Citi Raises Bitcoin Target to $113,000 as Crypto Outlook Improves 
Lynas Shares Slide on A$968 Million Meteoric Resources Deal 
Evernorth Set for Nasdaq Debut With 473 Million XRP Treasury 
Trump Praises Boeing 737 Max After Flydubai Crash Attempt 
XRP Ledger Hits 10 Million AI Payments as Bitcoin Retreats 
Airbus Spain Workers Approve Deal to End Months of Strikes 
Chainalysis AI Traces $387M Bitget Hack in Under 10 Minutes 
Bank of America Sees EUR/USD at 1.15 by Year-End 
MSTR Stock Rises 3% as Strategy Challenges MSCI Bitcoin Stance 
DogeOS Launches Testnet to Bring DeFi Apps to Dogecoin 
SoftBank Shares Fall After $10 Billion OpenAI Investment 
WordPress Malware Uses Ethereum to Evade Removal 
AAVE, PUMP, WLD and SKY Rally as Crypto Market Slips 
Nike Stock Slides as Revenue Miss Clouds Turnaround 
Add as a preferred source on Google
DALLAS and FORT WORTH, Texas, Feb. 28, 2017 -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that Vipin Garg, Ph.D., president and chief executive officer, will present a company overview at the upcoming Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 8:00 a.m. ET in Boston, MA.
A live webcast of the presentation will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODTTM, indicated for the treatment of ADHD in patients 6 years of age and older, is the first approved product using the Company’s extended-release (XR)-orally disintegrating tablet (ODT) technology platform. Neos, which is initially focusing on the treatment of ADHD, has filed New Drug Applications with the U.S. Food and Drug Administration for two other branded product candidates that are XR medications in ODT or oral suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®, an XR oral suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.1
1Tussionex® is a registered trademark of the UCB Group of Companies.
Contacts: Richard Eisenstadt Chief Financial Officer Neos Therapeutics (972) 408-1389 [email protected] Sarah McCabe Vice President Stern Investor Relations, Inc. (212) 362-1200 [email protected]
